Sekretessinställningar
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Aktiemarknader
    • BörsRealtidskurser, index och marknadsutveckling
    • MorgonrapportDaglig marknadssammanfattning och nattens viktigaste händelser
    • BörskalenderKommande resultat, noteringar och företagshändelser
    • UtdelningskalenderKommande och tidigare utdelningar
  • Bolag
    • BolagBläddra och filtrera hela listan över noterade bolag
    • UpptäckInspiration till din nästa investering
    • BörsnoteringarNya noteringar och kommande börsintroduktioner
    • ÅrsstämmorDatum för årsstämmor och aktieägarinformation
  • Aktieforskning
    • AktieanalysExpertaktieanalys och rekommendationer
    • ArtiklarNyheter, insikter och marknadskommentarer
    • PortföljInderes modellportfölj
    • inderesTVVideohub för aktieanalys, forskning och expertkommentarer
    • TranskriptionerFullständiga utskrifter av resultatsamtal och investerarmöten
    • AktiejämförelseJämför nyckeltal och utveckling för flera aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • BlankningSe vilka börsnoterade bolag som har offentliggjorda korta positioner
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Q&A
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer

Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.

Transkriptioner

Läs transkriptioner från webbsändningar och audiocasts

Transkriptioner

Läs transkriptioner från webbsändningar och audiocasts

Alla regioner
Sverige
Finland
Danmark
Norge
Senaste
Trendande
Följda

SenzaGen, Webcast, Q4'25

Av Inderes2026-02-13 08:00
SenzaGen

Ansvarsfriskrivning: Detta är en maskin­genererad transkription och kan innehålla felaktigheter.

Unknown 1
00:01 - 00:25

And here is Peter Nählstedt from SenzaGen, presenting the Q4 report and the full year 2025 financial performance, also covering the investment thesis. We will have a Q&A session after the presentation.

Peter Nählstedt
00:28 - 23:32

Welcome to his presentation of the Q4 and full year results. Fourth quarter report. They are presented. And all about GARD®. We stand firm, well stocked. SenzaGen ORA® database. Thereafter. Presentation of SenzaGen Group overview now. We will now cover the Strategic Initiatives plan from the Director of Capital Markets, and the new institutional international shareholders, following a vote in November. As Eiffel Investment Group. The report highlights strong GARD® sales. So we have the report, and so. So, in summary. Total net sales increased by 10%, which required significant effort. We have to constantly present. We set a new record for GARD® sales at 12.3 million SEK, representing an increase of 13% (or 10% FX-adjusted), with order intake contributing an additional 10% or 5%. 60%. We maintained the stability of our financial ledger in line with SenzaGen AB's normal operational performance, and we addressed an issue. The issue from which it stemmed. So far, 57% of the product mix comes from it. GARD® is even more central. And so we look at reducing our Opex by six and a half percent to 76 million, bringing it under control. During the year. Consequently, this resulted in a nearly flat EBIT, down 3%, and flat earnings per share, with an EBIT of -5 million SEK. In. EBIT was a marginal result. We adhere to IFRS, which we report on here from time to time, or other international standards. Still. Our order book was strong at the end of the year. We had a million orders. Now we go in with a six-million order book. A stark position for the outlook. And GARD®. There. Order intake, and the first sales we saw. Record for selling 10 to 12 million. We also recorded stronger direct order intake, including a half-million order from Stewart globally, and 2.5 million in global total backlog. So, in a new segment of technology. So, the 10% or 12% that we have from strategic net-new global groups, some are wondering about. Okay. Overall, we saw that 80% of our business came from repeat customers. So we have a solid foundation. Base business, or repeat business, as an automatic order. And then 85%. So it's a very broad, diversified customer base. Product mix. And later on, the overall percentage of tests completed for GARD® and some standard tests under OECD guidelines or complementary tests, resulted in a total that was a little larger but marginal. And so we sold and outsourced the tests, but also in-sourced testing again. So, whether tests come to us or are outsourced, now we see 6 to 8 GARD® tests that yield 50% repeat business. And for CROs, we have well over six examples. For. For example, ORA® is used for Clarins cosmetics from France and by BIC, a cosmetic or health-related company, as detailed on their website. So, you can find webinars on how to test for natural botanical extracts. For example, Google 'SenzaGen Clarins webinar'. For Sonova, which reports on medical technology, there are other relevant posts. Google Scholar. Search 'SenzaGen Sonova'. So, to elaborate. Sonova screens new materials. So. We also operate through our subsidiaries, VitroScreen and ToxHub. We are fortunate to have a focus on discipline and VitroScreen's culture at SenzaGen. To be frank, we are at an all-time low in sales, pipeline, and sales leads within our firm and also an unfair system. We implemented GARD® capacity at VitroScreen in Milan for better efficiency in managing a consistent workload and optimizing costs from management to operational ISO levels. So we are going to proceed, and we are confident of the full effect. Full effect for ToxHub. Some consultants talk about fantastic fifty percent growth for groups, with sales up from 10%. We are looking to expand into new segments or niches within this industry, and through collaboration, developing a group capable of generating cross-sales with a low cost of sales, targeting 13% to four and a half million, or leveraging the portfolio of user group offerings. So. These are some highlights from the culture without sugarcoating the company and the Group. At etc. Our focus is for better human health. By ensuring ethical product tests, SenzaGen Lund addresses 30% of concerns in some settings. The focus of our non-animal testing and toxicology GARD® platform. We have a blog at VitroScreen Milano. SenzaGen performs complete ORA® effect testing on a product or substance, using its ORA® platform, an organoid test platform capable of testing the substance's effects on multiple organs. So, the technique in Milano or in some settings involves personnel, or synergies with ToxHub, with 80% of its three employees and a network of other experts, who can provide regulatory risk and toxicological screening. Genotoxicity testing so that we can. Get. The job done. And the whole shift from testing to non-animal testing was more than 6.5%. Then net sales were $13 million. We are nearing an addressable market of half a million dollars. So for groups at. All of the firms find scientific or technical biological test models and come to use a range of tests for non-animal testing, which are cost-effective. And then. And your tests go further, and are then driven. Our testing will also apply to Europa and Nordamerika, covering Kosmetika. Meditech. Kemikalier. Lakemedel. Number. Strategic initiatives for accelerating execution. Our strategic objectives and future innovations. Further initiatives are aimed at establishing GARD® as a standard Medical Device technique. The deep dive and opening up the hood. Allergy test. Some methods are recognized as regulatory standards or achieve the status of an international organization, such as ISO, which validates them or works to establish GARD® as a standard method. We will also validate GARD®skin Dose-Response, and we will also focus on the genomic DNA aspects of GARD® to ensure its continued advancement. Now we are. Initiative to accelerate. Innovation and commercial organization for expanding our market. Reach. Forward. Strategic. Strategic initiatives going forward will be paid for upon completion of our growth plan. One of our strategic initiatives focuses on medical devices. So. Our GARD®skin Medical Device functions for an application that we have published, and we have now successfully concluded a ring trial demonstrating that GARD® performs effectively across three independent labs, yielding substantial results, and we offer a comprehensive test portfolio, including addressing some of the commonly reported significant parameters. The demand for dose response using GARD®skin Dose-Response, where we face challenges. But one can address issues related to concentration, or measure dose response; these evaluations can also be performed on a standalone basis. So we hope to receive the initial approval from ECVAM, which is the body that recommends test methods to the OECD, and this will also enable us to expand our reach, as we are establishing a robust global presence to secure strong repeat business. Our testing includes the Comet assay. Significant strides in building our presence at NIH or FDA for broader regulatory acceptance will go over for regulatory testing. So therefore, we also know that our distribution strategy involves American CROs, such as Eurofins USA, leveraging their ISO and scientific expertise. Clarins, BIC, Sonova, TGA. We have worked in parallel to broaden the test portfolio for completing the test or for GARD®skin. How we implemented EpiSensA as a skin sensitization test under review by the TGA. So we can send our product to market, and we have completed and implemented the SenzaGen VitroScreenORA® model. Then some commercial interest for the VitroScreenORA® cartilage organoid model. For example, in Medical Device applications, for an initial order, and also for prospective pipeline development, we are exploring additional endpoints. Future applications in sensitization, or substantial uses, even in genotoxicity in vitro or developmental toxicity, or using machine learning, or so-called in silico screening. So, from now. There we can break even soon. We break even with strict control. So at ORA®. Medical device. Accelerator. Growth in the acceleration phase. Driving market reach. Efterfrågan. Tests for medical devices. ISO 10993-10. In order to achieve FDA clearance for MedTech methods, we can offer comprehensive strategies. So we see then, indicative of impact. In vivo, ex vivo, and break-even are key aspects. In vitro advantages and stronger growth force. Stronger growth for our future. We therefore can scale up the method of testing for implementation. Ha! Eiffel Investment Group is a new institutional shareholder at SenzaGen AB. They have a strong and robust financial structure and are major international institutional investors. Eiffel Investment Group and international institutional investors. And €12 million assets under management, with long-term investments. Sustainable investing. Focus. We are aiming for circa 100 million kronor to 400 million, some of which is allocated for long-term investment, or to achieve strong VitroScreenORA® models by 2030, and to potentially accelerate our initiatives, manage capital for the company, support and commercialize the upscaling of strategic initiatives, and expand our regulatory activities. Our growth. Plan and break even. Force. Acceleration phase. Eiffel Investment Group has become a major institutional shareholder. So, for our top five list. SenzaGen AB. So, among our institutional investors, Eiffel Investment Group holds 4%, with Sonova, ShapeQ, and other commercial entities together representing a total of 6%. ShapeQ, a major institutional investor in the high-tech sector. Ålandsbanken ABP 3%. Professor Carl Borrebaeck and Laurent Inglebert, 5%. Laurent Inglebert holds 0.8% in SenzaGen AB. At the TGA. Services for in vitro testing, or pre-clinical testing, or for regulatory clearance for a test, or for assays at SenzaGen's technical labs. So, a warm welcome on board. A long time to build. Where we come from so far. We are starting strongly, and we have a record order book. Or we have a boost, or we are interested in backlog, totaling significant figures. Oh! Oh!

Unknown 1
23:35 - 23:50

Peter Nählstedt. That Nählstedt said. When was that?

Peter Nählstedt
23:56 - 24:20

We are ready. Speaking of the order book. We have over 2.5 million Kronor in our order book. Two GARD®. So, we have made good progress on both. So it looks a little better.

Unknown 1
24:26 - 24:43

Optimistic. Optimistic. And not so confident. And then. Q4. So confident in our success.

Peter Nählstedt
24:49 - 25:22

June 20th. Then, the annual international conference. We were optimistic. Booked. Momentum. Over 80% of our order intake. So, the combination of these factors is important. Our order book and we doubled our order intake. most optimistic you can have. In your TGA.

Unknown 1
25:23 - 25:30

I think the VitroScreen. So, the implementation of GARD® has constant demand for constant regulatory toxicity testing.

Peter Nählstedt
25:34 - 27:03

The VitroScreen CRO complement effect testing, or one can also say, at this cost for selling into new opportunities, generates interest for VitroScreen's Laurent Inglebert. They were booked up, and VitroScreen's commercial organization was operating effectively. So, there was a six-month sales cycle when we built up a strong sales pipeline for accelerating growth. That's not easy. We know. A year or so later, we will also work towards better efficiency at VitroScreen. So therefore. So, implementing GARD®, which has constant demand for the consistent scope of testing requirements. Let's get on with projects and laboratory resources and so forth. Set on science. By upper management. Costs.

Unknown 1
27:08 - 27:18

ToxHub. and. 90% of your information from SenzaGen AB.

Peter Nählstedt
27:19 - 28:12

ToxHub Landolfi has grown very, very quickly. Toxicology or. Industry or job related to ToxHub. And we can go to the whole section, the over/under three. Oh, it's a little longer than an hour. I talked to over there. Biologists, Italians. Biolog. Italian, German, or an international group.

Unknown 1
28:16 - 28:31

It is from. India. But. So can you take a look at it?

Peter Nählstedt
28:35 - 29:20

Yeah. We all have some focus. The entire 3 billion and VitroScreen management. Personnel and build our organization. Higher internal efficiency. We have the testers. The right man for the job. Key thing. Okay. Animal test process under threat. And so if they're not then in focus, or a cost-effective alternative, or an effective position.

Unknown 1
29:24 - 29:43

Any negative effect on sales or revenue? So the cost. Offset. Cost-effective. Can you describe the key factors?

Peter Nählstedt
29:44 - 30:34

For example, the factors I'm alluding to a Eurodollar, or in fact, for the short-term impact, and some of the factoring them in. 3760 EUR. So therefore. So we are at a gross margin at or above zero. So also okay. And we can. And we can learn some offset and solutions.

Unknown 1
30:37 - 30:58

They are also factoring in financial costs and miscellaneous. Of course not. Okay. From Gustav Mayer for Redeye, I'm going to order a report.

Peter Nählstedt
31:01 - 31:06

And the GARD® process for OECD.

Unknown 1
31:08 - 31:16

So after. The.

Peter Nählstedt
31:19 - 31:44

End of an era for a man. Right. So, just for some repeat orders and new first orders. So, our order.

Unknown 1
31:46 - 31:56

So, hold on, just for some repeat orders and first orders. Tests are underway. Then.

Peter Nählstedt
31:59 - 32:35

VitroScreen. Studies that we perform GARD® tests. Can you go in 2 or 3? Tests in study. How much? B12, 300. Studio pharma models 250, 250. So then still working at VitroScreen. The average is over 30%.

Unknown 1
32:39 - 33:09

So, just for some repeat business and new order intake. In. FL. The in France. The family still provides funding for. For. For me, for who I.

Peter Nählstedt
33:16 - 34:28

And as a professional in life sciences, I am in a position to speak for investors regarding SenzaGen AB. Or, for an institutional investor, SenzaGen is legitimate. They get some form of criteria. So they have our technology, which allows them to serve this niche, and this year, we focused on the GARD® platform and addressed macro trends in in vitro toxicity testing, which received significant attention. Let's go. So we took the uplift and then an investor. Investor and any investor. More on the commercial. Commercial concept.

Unknown 1
34:29 - 34:46

Okay. And lastly. That our ambition exemplifies SenzaGen's vision, highlighting progress on strategic initiatives.

Peter Nählstedt
34:46 - 35:16

So a normal setup for some. So then you. Intro. Direct representation. Your system, our platform. System activation was also an ideal pre-clinical biological assay. Webcasts. Frank. Stella.

Unknown 1
35:18 - 35:46

Okay. Total. And. 70 million from overall sales. 70 million from our overall sales. So the liquidity. So the liquid. Thinking about them. Potential can be used for.

Peter Nählstedt
35:47 - 37:32

Yeah. Okay. So we can say that. We hope they are correct? They had their. Our financial position and burn rate were optimized to meet our strategic objectives for the capital raise. Oh man. Capital markets also saw that we had financing for our plan. So, at Eiffel, the year saw stronger activities. And we also have to accelerate. Management plans. It involves conducting R&D to ensure a comprehensive initiative. The initiative and the lack of capacity to continue our momentum. Customers. Customers, or then. It has in-licensing or insourcing of a completed test portfolio. So there was also better perception. So, aim for the target, Eiffel, for an institutional and international investor, or for an initiative within the plan.

Unknown 1
37:35 - 37:46

The roadmap. From a recent event, we also hosted a webinar featuring Peter's presentation.

Peter Nählstedt
37:47 - 37:49

Thank you very much.

Till webcasten
Pierce Group, Audiocast, Q3'26
Språk: Engelska2026-11-13 08:00
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Språk: Engelska2026-11-12 10:00
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Språk: Engelska2026-11-12 09:00
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Språk: Engelska2026-11-12 08:00
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 08:00
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Språk: Svenska2026-11-12 08:00
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 08:00
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Språk: Engelska2026-11-12 07:15
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Språk: Engelska2026-11-11 13:00
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Språk: Engelska2026-11-11 13:00
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Språk: Engelska2026-11-11 12:30
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Språk: Engelska2026-11-11 09:00
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Språk: Engelska2026-11-11 09:00
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Språk: Engelska2026-11-10 17:00
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Språk: Engelska2026-11-10 08:00
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Språk: Engelska2026-11-10 08:00
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Språk: Svenska2026-11-06 09:00
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Språk: Engelska2026-11-06 09:00
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…